Impulse News

First Patient Enrolled in International CCM™ Clinical Study for Heart Failure with Preserved Ejection Fraction at Karolinska University Hospital

Stuttgart, Germany, October 22nd 2018 – The first patient was enrolled in Impulse Dynamics’ international multi-center clinical trial testing the efficacy and safety of its CCM™ technology in heart failure patients with preserved Ejection Fraction (CCM™-HFpEF).  Cardiac contractility modulation is an established device based therapy shown in several international multicenter randomized controlled trials to be […]

Read more

Clinical Registry Data and recently published FIX-HF-5C were presented at the Late-Breaking Clinical Trial Session at EHF 2018

Stuttgart, Germany, May 28th, 2018 – Impulse Dynamics Germany, GmbH announced results on “Real World” experience from its European Clinical Registry. The results were presented today by Prof. Gerd Hasenfuß, MD, Professor of Internal Medicine and Director of the Heart Center, University Hospital Göttingen, Germany at the Late-Breaking Clinical Trials Session of the European Heart […]

Read more

FIX-HF-5C Late-Breaking Clinical Trial Data Presented at HRS 2018 with Simultaneous Publication in the JACC: Heart Failure

Orangeburg, New York, May 10, 2018 – Impulse Dynamics (USA), Inc. announced results from its FIX-HF-5C randomized, Controlled Trial of Cardiac Contractility Modulation in Heart Failure. The study results were presented by Prof. William Abraham, MD, Professor of Internal Medicine and Director, Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, at the […]

Read more

The CFDA Approves Impulse Dynamics’ Optimizer System for Treatment of Chronic Heart Failure in China

Orangeburg, New York & Stuttgart, Germany. December 18, 2017 – The China Food and Drug Administration (CFDA) has approved Impulse Dynamics’ Optimizer® system for treatment of chronic heart failure.  The announcement was made on December 12, 2017 by Impulse Dynamics’ CEO, Dr. Simos Kedikoglou.  “This is a major milestone for Impulse Dynamics, as it will help […]

Read more

– „I feel like I have won the lottery!“

Ulla Magnusson, today 80 years old, was implanted with an Optimizer® device for cardiac contractility modulation treatment of her chronic heart failure at Karolinska university hospital two years ago. Ulla describes how fatigue and shortness of breath started to take over her life about 5 years ago and how it affected her everyday living: “It […]

Read more

New device based treatment for patients with Chronic Heart Failure now available in the Nordic region

Cardiac contractility modulation (CCM) is a device based therapy which EU Studies have shown to be an effective treatment option for patients with Chronic Heart Failure (CHF). CCM therapy will now be made available to patients in the Nordic region by consultation with their treating doctors. An estimated 250 000 individuals in Sweden suffer from […]

Read more

Impulse Dynamics Announces First US Implant in the FIX-HF-5CA Continued Access Study.

Orangeburg, New York. August 7, 2017 – Impulse Dynamics announced today the first implant in the Company’s FIX-HF-5CA Continued Access Study. The FIX-HF-5CA study is a multicenter, prospective, single-arm Continued Access evaluation of the company’s Cardiac Contractility Modulation (CCM) device. Impulse Dynamics proprietary CCM technology delivers non-excitatory electric pulses to the cardiac muscle with the […]

Read more

Impulse Dynamics Completes $45 million Financing Round

Stuttgart, May 11, 2017 – Impulse Dynamics, developer of the revolutionary Cardiac Contractility Modulation (CCM) technology for treatment of Chronic Heart Failure (CHF), announced today that the company has closed a $45 million financing round. The equity financing round was led by Goldstone Investment, a global investment company belonging to the Chinese conglomerate CITIC Securities, […]

Read more

Randomization of the FIX-HF-5C Confirmatory Study Completed

Orangeburg, New York, March 31, 2017 — Impulse Dynamics is pleased to announce that it has successfully completed enrollment of the 160 subjects required for its FIX-HF-5C Confirmatory Study. The FIX-HF-5C Study is a prospective, multicenter, randomized study to evaluate the safety and efficacy of cardiac contractility modulation (CCM) signals delivered by the implantable Optimizer […]

Read more
Page 1 of 612345...Last »